A Study on IB-001 Dose Response and Tolerability in Healthy Adults and Those With Chronic Hepatitis B

A Phase 1, Randomized, Double-Blinded, Placebo-Controlled Study to Evaluate Safety, Tolerability, Pharmacokinetics, And Preliminary Efficacy of Single and Multiple Ascending Doses of IB-001 in Healthy Participants and Participants With Chronic Hepatitis B

This study will examine the safety and tolerability of single and multiple doses of IB-001, and will be conducted in two parts:

Part A: SAD study in approximately 50 Healthy Volunteers (HV). Part B: MAD study in approximately 30 adult participants living with Chronic Hepatitis B (CHB).

Study Overview

• Status: Recruiting
• Conditions: Chronic Hepatitis B Virus Infection
• Intervention / Treatment: Drug: IB-001; Other: Placebo

Detailed Description

This is a first-in-human, double-blind, randomized, placebo-controlled Phase 1 study of IB-001 administered subcutaneously to evaluate safety, tolerability, PK/PD, and preliminary antiviral activity.

The study is comprised of two parts:

Part A: Single-dose, multicohort, dose-finding study in approximately 50 adult Healthy Volunteers (HV) in up to five cohorts (n=10 per cohort; 8 active:2 placebo). Participants will receive a single sub-cutaneous dose of investigational product followed by a 28-day post treatment follow-up.

Part B: Multidose, multicohort study in Treatment-Naïve or Currently-Not-Treated Adults with Chronic Hepatitis B (CHB).

Approximately 30 adult participants (up to 3 cohorts; n=10 per cohort; 8 active:2 placebo). Once-weekly sub-cutaneous dosing over 4 weeks with 6-week post-treatment follow-up. Dose recommendations in both Part A and Part B will be made by the Safety Review Committee (SRC) based on review of emerging safety data.

• Study Type: Interventional
• Enrollment (Estimated): 80
• Phase: Phase 1

Contacts and Locations

• Study Contact: Name: Nick Hourguettes; Phone Number: +1 240 656 2820; Email: ClinOps@integer.bio
• Study Contact Backup: Name: Carey Hwang, MD, PhD; Phone Number: +1 615 491 2553; Email: ClinOps@integer.bio

Study Locations

• Moldova
  • Chisinau, Moldova, 2025
    • Not yet recruiting
    • Arensia Exploratory Medicine Chisinau
    • Contact: Alina Juvoc
• New Zealand
  • Auckland
    • Auckland, Auckland, New Zealand, 1010
      • Recruiting
      • New Zealand Clinical Research
      • Contact: Edward Gane, MBChB, MD; Phone Number: 22922 +64 021548371; Email: EdGane@adhb.govt.nz
      • Principal Investigator: Edward Gane, MBChB, MD

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: Yes

Description

PART A: Healthy Volunteers

Inclusion Criteria:

1. Able and willing to provide written informed consent.
2. Male or female aged 18 to 70 years.
3. Females must not be of childbearing potential OR those who are of childbearing potential must be non-pregnant and non-lactating and willing to use a highly effective method of contraception. Males whose partners are of childbearing potential must either be surgically sterile or willing to use a highly effective acceptable method of contraception.
4. Non-tattooed, clear injection site suitable for SC injection and monitoring in the opinion of the Investigator.

Exclusion Criteria:

Healthy Volunteer participants must not meet any of the following criteria at Screening or upon admission to the site (on Day -1).

1. Major surgery requiring general anesthesia within 12 weeks prior to Screening or is expected to have surgery requiring general anesthesia during the course of the study.
2. History of severe allergic or anaphylactic reactions, or sensitivity to the IP or its constituents.
3. Blood donation or blood loss of ≥ 1 unit (450 mL) of whole blood within 4 weeks before Screening or plasma donations within 7 days prior to dosing of investigational product (IP).
4. Any underlying medical condition (including but not limited to gastrointestinal, renal, hepatic, neurological, hematological, endocrinological, tumor, pulmonary, immune, mental, or cardiovascular and cerebrovascular diseases).
5. History of malignancy, except for non-melanoma skin cancer, excised more than 1 year prior to Screening or cervical intraepithelial neoplasia that has been successfully cured more than 5 years prior to Screening.
6. Current hepatitis A virus (HAV) infection, hepatitis B virus (HBV) infection, hepatitis C virus (HCV) infection.
7. Positive test for HIV-1 or HIV-2 antibodies.
8. Any other active infection requiring systemic antiviral or antimicrobial therapy that will not be completed within 2 weeks of first dosing.
9. Clinically significant abnormalities on Screening ECG or history of cardiac arrhythmias, risk factors for Torsade de Pointes (hypokalemia, hypomagnesemia, decompensated heart failure and acute myocardial infarction), and a QTcF > 450 ms (males) or QTcF > 470 ms (females) at Screening.
10. Physical examination findings at Screening that are considered clinically significant by the Investigator and likely to adversely impact study conduct and/or interpretation.
11. Clinically significant abnormal vital signs
12. Laboratory abnormalities considered clinically significant by the Investigator at Screening. From Cohort A3 onwards, participants with blood platelet counts < 150 × 109/L or absolute neutrophil counts < 1.5 × 109/L will be excluded.
13. Use of any prescribed or over-the-counter medications (including vitamins or herbal remedies) within 2 weeks of first dosing or within 5 times the elimination half-life of the medication prior to first dosing.
14. Any suspicion or history of drug and/or alcohol abuse within the last year.
15. Pregnant or planning to become pregnant during the course of the study, or currently breastfeeding.
16. Use of more than 5 cigarettes, or equivalent, a day in the 3 months prior to Screening. Is unwilling to abstain from nicotine-containing products for 48 hours prior to admission to the site and during the in-house stay at the clinical research unit.
17. Receipt of any investigational drug or product within 90 days of Study Day 1 or within 5 times the elimination half-life of the medication prior to first dosing with the IP, whichever is earlier. Receipt of an invasive medical device within 90 days before first dosing with the IP that in the opinion of the PI or designee may impact the ability of the participant to complete all protocol-required procedures. Participants must not have participated in interventional clinical studies more than 4 times per year.
18. Use of any prescribed or over-the-counter medications (including vitamins, supplements, or herbal remedies) within 2 weeks of first dosing with the IP or within 5 times the elimination half-life of the medication prior to first dosing with the IP (whichever is longer). Note: Simple analgesia (paracetamol < 2 g/day, nonsteroidal anti-inflammatory drug [NSAID] at therapeutic doses) may be permitted at the discretion of the PI, and may only be used as premedication prior to dosing of IP if recommended by the SRC.
19. Has received live vaccine(s) within 28 days of Screening or plans to receive live vaccines within 28 days of dosing with the IP on Study Day 1. Note: COVID-19 vaccines are not considered live vaccines.
20. Any suspicion or history of drug and/or alcohol abuse within the last year.
21. Positive toxicology Screening panel (urine test including qualitative identification of tetrahydrocannabinol, cocaine, amphetamines, benzodiazepines, opiates, methadone, methamphetamines, ecstasy, and phencyclidine).
22. Positive alcohol breath test at Screening and/or on Study Day -1.
23. History (within 90 days of Screening) of alcohol consumption exceeding 2 standard drinks per day on average (1 standard drink = 10 grams of alcohol). Alcohol consumption will be prohibited at least 48 hours before dosing with the IP on Study Day 1, and during the in-house stay at the clinical research unit.
24. Uses more than 5 cigarettes, or equivalent, per day in the 3 months prior to Screening, and/or is unwilling to abstain from nicotine-containing products for 48 hours prior to admission to the site and during the in-house stay at the clinical research unit.
25. Pregnant (positive serum pregnancy test at Screening or a positive urine pregnancy test predose on Study Day -1), planning to become pregnant during the course of the study, or currently breastfeeding.
26. Any other factor that makes it inappropriate for study participation per the Investigator's judgment.

PART B: Participants with Chronic Hepatitis B (CHB)

Inclusion Criteria:

1. Able and willing to provide written informed consent.
2. Male or female aged 18 to 70 years,
3. BMI between 18 and 35 kg/m2.
4. Females must not be of childbearing potential OR those who are of childbearing potential must be non-pregnant and non-lactating and willing to use a highly effective method of contraception. Males whose partners are of childbearing potential must either be surgically sterile or willing to use a highly effective acceptable method of contraception.
5. Diagnosed with CHB and are HBeAg-negative (on 2 occasions at least 6 months apart) and have HBsAg titers of ≥ 100 IU/mL at Screening.
6. Participants must be treatment naive (i.e., have never received treatment with HBV antiviral medicines [NUCs, IFN] or an investigational anti-HBV agent) or currently not treated (i.e., not been on treatment with approved [NUCs, IFN] or investigational anti-HBV medicines within 12 months prior to randomization).
7. Vital signs and physical examination are normal, or abnormal values are not clinically significant in the opinion of the Investigator.

Exclusion Criteria:

1. Evidence or history of liver disease of non-HBV etiology, including but not limited to HAV, HCV, HDV, or HEV (endemic regions only) infections; drug- or alcohol-related liver disease; autoimmune hepatitis; hemochromatosis; Wilson's disease; α-1 antitrypsin deficiency; primary biliary cirrhosis; primary sclerosing cholangitis; non-alcoholic steatohepatitis; or any other non-HBV liver disease considered clinically significant by the Investigator. Participants with metabolic dysfunction-associated steatotic liver disease without any signs of steatohepatitis or those with documented Gilbert's Syndrome, are eligible.
2. Diagnosed or suspected hepatocellular carcinoma (HCC).
3. Significant liver fibrosis or cirrhosis (FibroScan result > 8.5 kPa within 12 months of Screening; Prior liver biopsy with Metavir F3 fibrosis or F4 cirrhosis within 2 years of Screening; AST-to-Platelet Index (APRI) > 1 and FibroTest result > 0.5 within 12 months of Screening).
4. Positive for HIV-1 or HIV-2 at Screening.
5. Active infection requiring systemic antiviral or antimicrobial therapy that will not be completed within 2 weeks of first dosing of investigational product (IP).
6. Any of the following clinical laboratory values at Screening: ALT or AST ≥ 3 × ULN; blood platelet counts < 120 × 109/L; absolute neutrophil count < 1.3 × 109/L; hemoglobin < 10.0 g/dL; serum total bilirubin ≥ 1 × ULN (Note: for participants with documented Gilbert's Syndrome, total bilirubin ≥ 2 × ULN is acceptable); serum albumin < 35 g/L; eGFR of < 60 mL/min/1.73 m2; INR > 1.2 × ULN.
7. History of severe allergic or anaphylactic reactions, or sensitivity to the IP or constituents.
8. Blood donation or blood loss of ≥ 1 unit (450 mL) of whole blood within 4 weeks before Screening or plasma donations within 7 days prior to first dosing with the IP.
9. History or presence of immune-mediated disease (e.g., systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, autoimmune hepatitis, sarcoidosis, psoriasis of greater than mild severity, autoimmune uveitis), or cerebrovascular, chronic pulmonary or cardiac disease associated with functional limitation, retinopathy, uncontrolled thyroid disease (thyroid stimulating hormone [TSH] > 10 or < 0.4 mU/L), or uncontrolled seizure disorder, as determined by the Investigator. Participants who are positive for anti-thyroglobulin antibodies or anti-thyroid peroxidase antibodies will be excluded.
10. History or presence of significant (as judged by the Investigator) cardiovascular, respiratory, renal, gastrointestinal, endocrine, hematological disorders, or diagnosed central or peripheral neurological disease, capable of significantly altering the absorption, metabolism, or elimination of drugs, of constituting a safety-related risk when taking the study treatment, requiring premedication, or of interfering with the interpretation of the data.
11. Clinically significant 12-lead ECG abnormalities on Screening ECG or history of cardiac arrhythmias, risk factors for Torsade de Pointes (hypokalemia, hypomagnesemia, decompensated heart failure and acute myocardial infarction), and cardiac arrhythmias, risk factors for Torsade de Pointes (hypokalemia, hypomagnesemia, decompensated heart failure and acute myocardial infarction), and QTcF > 450 ms for males or QTcF > 470 ms for females at Screening.
12. Physical examination findings that are considered clinically significant by the Investigator and likely to adversely impact study conduct and/or interpretation.
13. Clinically significant abnormal vital signs, confirmed with retesting after at least 5 minutes of additional rest.
14. History (within 90 days of Screening) of alcohol consumption exceeding 2 standard drinks per day on average (1 standard drink = 10 grams of alcohol).
15. Positive alcohol breath test at Screening and/or on Study Day 1. Alcohol consumption will be prohibited at least 48 hours before each dose with the IP, and during any in-house stays in the clinical research unit or investigational site (if applicable).
16. Use of more than 5 cigarettes per day or equivalent (e.g., cigarettes, vapes, nicotine patches, cigars, chewing tobacco) in the 3 months prior to Screening. Nicotine-containing products (eg, cigars, cigarettes, vapes) will be prohibited at least 48 hours before each dose with the IP, and during any in-house stays in the clinical research unit or investigational site (if applicable).
17. Participants must not have participated in interventional clinical studies more than 4 times per year. Receipt of any investigational drug or product within 90-days of Study Day 1 or within 5 times the elimination half-life of the medication prior to first dosing with the IP, whichever is earlier. Receipt of a device within 90 days before first dosing with the IP that in the opinion of the Investigator may impact the ability of the participant to complete all protocol-required procedures or testing.
18. Received solid organ or bone marrow transplant.
19. Any immunosuppressing, immunomodulator (e.g., thymosin) or cytotoxic drug administrations within 6 months before first dosing with the IP (Day 1).
20. Received any antiplatelet (e.g., aspirin, clopidogrel) or antithrombotic therapy (e.g., warfarin, dabigatran, apixaban) within 14 days prior to first dosing with the IP and throughout the study.
21. Has received live vaccine(s) within 28 days of Screening or plans to receive live vaccines within 28 days of dosing with the IP. Note: COVID-19 vaccines are not considered live vaccines.
22. Use of corticosteroids above 5 mg/day of prednisone (or equivalent) or other immunosuppressive medications within 4 weeks prior to Screening. Note: topical, intra-articular and inhaled steroids allowed.
23. Use of any herbal medicines or supplements within 3 months prior to Screening visit that are known to be hepatotoxic based on Investigator's opinion or who have initiated any new herbal medicine or supplement within 30 days prior to Study Day 1. Eligibility to participate should be discussed with the Sponsor's medical representative.
24. Pregnant (positive serum pregnancy test at Screening or a positive urine pregnancy test predose on Study Day 1), planning to become pregnant during the course of the study, or currently breastfeeding.
25. Any other factor that makes it inappropriate for study participation per the Investigator's judgment.

Other prohibited medications during the study: Treatments that may increase ALT or AST (eg, augmentin, > 2 g paracetamol/day, initiating treatment with an HMG-CoA [3-hydroxy-3-methylglutaryl coenzyme A] reductase inhibitor [statins]) should be avoided. The use of these drugs, if necessary, should be discussed with the PI or Sponsor's medical representative or designee, preferably before initiation of their administration. Simple analgesia (paracetamol < 2 g/day, NSAID at therapeutic doses) may be prescribed as premedication prior to dosing of IP, if recommended by the SRC.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Triple

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Arm 1: IB-001; Participants receive IB-001, administered subcutaneously according to the assigned cohort schedule. In Part A, participants receive a single dose. In Part B, participants receive once-weekly dosing for 4 weeks.	Drug: IB-001; IB-001 is an investigational product targeting the type I IFN (IFN-I) signaling pathway. Subcutaneous (SC) injectable formulation; single doses in HVs (Part A) and weekly doses for 4 weeks in CHB participants (Part B). Exact dose levels recommended by SRC.
Placebo Comparator: Arm 2: Placebo; Participants receiving placebo, follow the same dosing schedule as the active arm (single dose in Part A; once-weekly for 4 weeks in Part B).	Other: Placebo; Sodium Chloride (NaCl) 0.9 % administered subcutaneously as a single dose (Part A) and weekly dose for 4 weeks (Part B).

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Part A and Part B: Incidence and Severity of Treatment-Emergent Adverse Events (TEAEs).	Treatment-Emergent Adverse Events (TEAEs) are adverse events that first appear or worsen in severity during the course of the clinical study, regardless of whether they are related to the investigational product (IP) or not. TEAEs will be coded using MedDRA and summarized by SOC, PT, severity, and relationship to IP. Treatment-related AEs (possibly/probably/definitely related) will also be summarized separately. A by-participant AE listing will be provided	Through Day 29 (Part A), through Day 64 (Part B).
Part A and Part B: Number of Participants with Adverse Events (AEs) by Severity	An AE is any unfavorable medical occurrence in a study participant administered an investigational product. The AE does not necessarily have a causal relationship with the treatment. All AEs will be graded for severity according to NCI-CTCAE classification. If an appropriate AE term is not found in NCI-CTCAE, the AE will be graded as follows: Grade 1 (mild); Grade 2 (Moderate); Grade 3 (Severe); Grade 4 (Severe) and Grade 5 (Death).	Through Day 29 (Part A), through Day 64 (Part B)
Part A and Part B: Number of Participants with Adverse Events (AEs) of Special Interest (AESIs)	AEs of special interest include Cytokine Release Syndrome (CRS), Injection Site Reactions (ISRs) and Unexplained Liver Biochemistry Elevations. Reported AESIs will be graded according to NCI-CTCAE classification. If an appropriate AE term is not found in NCI-CTCAE, the AESI will be graded as follows: Grade 1 (mild); Grade 2 (Moderate); Grade 3 (Severe); Grade 4 (Severe) and Grade 5 (Death).	Through Day 29 (Part A), through Day 64 (Part B)
Part A and Part B: Number of Participants with Clinically Significant Changes in Laboratory Parameters	Assessment Method - Number of participants with clinical laboratory abnormalities (serum chemistry, hematology, and coagulation) will be reported.	Through Day 15 (Part A), through Day 64 (Part B)
Part A and Part B: Number of Participants with Clinically Significant Changes in Vital Signs.	Number of participants with vital signs abnormalities will be reported. Vital signs include body temperature, pulse rate, respiratory rate, and blood pressure.	Through Day 15 (Part A), through Day 64 (Part B)
Part A and Part B: Number of Patients with Clinically Significant Changes in Cardiac Parameters.	Number of participants with electrocardiogram (ECG) abnormalities will be reported.	Through Day 15 (Part A), through Day 64 (Part B)

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Part A and Part B: Number of Patients with Clinically Significant Anti-Drug Antibodies (ADAs).	All immunogenicity data (ADA) are to be analyzed using the Immunogenicity Analysis Population. ADA incidence and titer levels over time will be summarized by dose.	Through Day 29 (Part A), through Day 64 (Part B)
Part B: Changes from Baseline in HBsAg levels over time.	Blood samples will be analyzed for HBsAg levels to establish baseline and determine eligibility; subsequent blood samples will be collected at protocol-specified timepoints to measure HBsAg changes over time.	Through Day 64 (Part B)
Part B: Change from Baseline in Anti-HBs Antibody Titers over time.	Blood samples will be collected at baseline and at protocol-specified timepoints to measure anti-HBs antibody titer changes over time.	Through Day 64
Part B: Reduction from Baseline in HBV DNA levels over time.	Blood samples will be collected at baseline and at protocol-specified timepoints to measure HBV DNA changes over time.	Through Day 64
Part A and Part B: PK Parameter - Maximum Observed Serum Concentration (Cmax) of IB-001	The Cmax is the maximum observed concentration of IB-001 in serum following single or multiple ascending dose administration. Blood samples will be collected at baseline and at protocol-specified timepoints.	Through Day 29 (Part A), through Day 64 (Part B)
Part A and Part B: PK Parameter - Area under the Serum Concentration Time Curve (AUC) of IB-001.	AUC is the area under the concentration time curve of IB-001 in serum following single or multiple ascending dose administration. Blood samples will be collected at baseline and at protocol-specified timepoints.	Through Day 29 (Part A), through Day 64 (Part B)
Part A and Part B: PK Parameter - Time to Observed Maximum Serum Concentration (Tmax) of IB-001.	Tmax is the time it takes to reach maximum concentration of IB-001 in serum following single or multiple ascending dose administration. Blood samples will be collected at baseline and at protocol-specified timepoints.	Through Day 29 (Part A), through Day 64 (Part B)
Part A and Part B: PK Parameter - Terminal Half Life (T1/2) of IB-001.	T1/2 will be measured following single and multiple doses of IB-001. Blood samples will be collected at baseline and at protocol-specified timepoints.	Through Day 29 (Part A), through Day 64 (Part B)

Collaborators and Investigators

• Sponsor: IntegerBio
• Investigators: Principal Investigator: Edward Gane, MBChB, MD, FRACP, MNZ, New Zealand Clinical Research

Study record dates

Study Major Dates

• Study Start (Actual): February 20, 2026
• Primary Completion (Estimated): April 30, 2027
• Study Completion (Estimated): July 1, 2027

Study Registration Dates

• First Submitted: January 16, 2026
• First Submitted That Met QC Criteria: January 28, 2026
• First Posted (Actual): February 5, 2026

Study Record Updates

• Last Update Posted (Actual): July 2, 2026
• Last Update Submitted That Met QC Criteria: June 30, 2026
• Last Verified: June 1, 2026

More Information

Terms related to this study

• Keywords: HBV; First in Human; Dose finding; Hepatitis B virus; Chronic Hepatitis B; Dose Ranging
• Additional Relevant MeSH Terms: Blood-Borne Infections; Pathologic Processes; Chronic Disease; Disease Attributes; Infections; Virus Diseases; Digestive System Diseases; Liver Diseases; Hepatitis, Viral, Human; Communicable Diseases; DNA Virus Infections; Hepadnaviridae Infections; Hepatitis, Chronic; Hepatitis; Pathological Conditions, Signs and Symptoms; Hepatitis B; Hepatitis B, Chronic
• Other Study ID Numbers: IB001-001

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No